NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Diversified (“CODI” or the “Company”) (NYSE: CODI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CODI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 7, 2025, CODI i ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Compass Diversified (“Compass” or the “Company”) (NYSE:CODI) on behalf of Compass stockholders. Our investigation concerns whether Compass has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...

Core Viewpoint - Compass, Inc. reported a quarterly loss of $0.05 per share, which was better than the Zacks Consensus Estimate of a loss of $0.06, showing an earnings surprise of 16.67% [1] Financial Performance - The company posted revenues of $1.36 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.16%, compared to $1.05 billion in the same quarter last year [2] - Over the last four quarters, Compass has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Compass shares have increased approximately 30.8% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $2.1 billion, and for the current fiscal year, it is $0.09 on revenues of $7.02 billion [7] - The estimate revisions trend for Compass is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Internet - Software industry, to which Compass belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Core Viewpoint - DJS Law Group is investigating claims on behalf of investors of Compass Diversified for potential violations of securities laws [1] Investigation Details - The investigation has identified irregularities in Lugano's non-CODI financing, accounting, and inventory practices [2] - Moti Ferder, the founder and CEO of Lugano, resigned from all positions effective May 7, 2025, without receiving severance compensation [2] DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and M&A appraisals [3] - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3]

Core Insights - Compass, Inc. reported a revenue increase of 28.7% year-over-year in Q1 2025, reaching $1.4 billion, driven by a 27.8% increase in total transactions, while the overall market saw a decline of 2.1% [5][2][21] - The company achieved a record operating cash flow of $23.1 million, marking a 169% year-over-year growth, and free cash flow of $19.5 million, making it the fifth consecutive quarter of positive free cash flow [2][5][36] - Compass's quarterly market share grew to 6.0%, an increase of 125 basis points year-over-year, with organic market share up 82 basis points [2][5][21] Financial Performance - The net loss for Q1 2025 was $50.7 million, an improvement from a net loss of $132.9 million in Q1 2024, with non-cash stock-based compensation expenses of $30.4 million and depreciation and amortization of $28.8 million included in the loss [5][32][35] - Adjusted EBITDA for Q1 2025 was $15.6 million, a significant improvement from a loss of $20.1 million in Q1 2024 [5][35] - Operating expenses grew by 11.5% year-over-year, while revenue grew by 28.7%, indicating effective cost control [2][5] Operational Highlights - The number of principal agents increased by 41.6% year-over-year to 20,656, with a strong retention rate of 96.6% [5][2][25] - Total transactions closed by Compass agents reached 49,121 in Q1 2025, reflecting a 27.8% increase compared to the previous year [5][27] - Gross Transaction Value (GTV) was $52.4 billion, up 31% from $40.1 billion in Q1 2024, with organic GTV at $47.3 billion [5][28] Strategic Initiatives - The Compass 3-Phased Price Discovery and Marketing Strategy saw adoption by 48.2% of homeowners listing their homes, leading to faster sales and fewer price drops compared to non-pre-marketed listings [9][6][30] - The company launched several technology features, including Compass One and One-Click Title & Escrow Integration, aimed at enhancing agent efficiency and client engagement [9][6][20] - The outlook for Q2 2025 anticipates revenue between $2.0 billion and $2.15 billion, with Adjusted EBITDA projected at $115 million to $135 million [9][10]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to limited upside or downside risks [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: Company Analysis - Compass, Inc. (COMP) - Compass, Inc. (COMP) has shown a price increase of 1.7% over the past four weeks, indicating growing investor interest [4] - The stock has gained 4% over the past 12 weeks, with a beta of 2.8, suggesting it moves 180% higher than the market in either direction [5] - COMP has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] - An upward trend in earnings estimate revisions has led to a Zacks Rank 2 (Buy) for COMP, which is associated with strong momentum effects [7] - COMP is trading at a Price-to-Sales ratio of 0.71, suggesting it is undervalued at 71 cents for each dollar of sales [7] Group 3: Additional Investment Opportunities - Besides COMP, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Core Viewpoint - The market anticipates Compass, Inc. (COMP) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025 [1][2]. Earnings Expectations - The earnings report is expected to be released on May 8, 2025, with a consensus estimate of a quarterly loss of $0.06 per share, reflecting a year-over-year improvement of +77.8% [3][12]. - Revenues are projected to reach $1.42 billion, representing a 34.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 15.63% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Compass is higher than the Zacks Consensus Estimate, leading to an Earnings ESP of +21.05% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Compass currently holds a Zacks Rank of 2, suggesting a high likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Compass was expected to post a loss of $0.09 per share but actually reported a loss of $0.08, resulting in a surprise of +11.11% [12]. - Over the past four quarters, Compass has exceeded consensus EPS estimates three times [13]. Conclusion - Compass is positioned as a compelling candidate for an earnings beat, but investors should consider other influencing factors before making investment decisions [16].

Core Insights - Compass, Inc. is a leading tech-enabled real estate services company and the largest residential real estate brokerage in the U.S. by sales volume, participating in the 53rd Annual J.P. Morgan TMC Conference on May 14, 2025 [1][4] Company Overview - Founded in 2012 and based in New York City, Compass provides an end-to-end platform for residential real estate agents, enhancing their service delivery to clients [3] - The platform includes a suite of cloud-based software for customer relationship management, marketing, client service, and brokerage services, specifically tailored for the real estate industry [3] - Compass has been ranked as the number one real estate brokerage by sales volume for 2024 by Real Trends, marking its fourth consecutive year in this position [4] Event Participation - CEO Robert Reffkin will participate in a fireside chat at 3:00 p.m. ET, with CFO Kalani Reelitz conducting one-on-one meetings with investors throughout the day [2] - The fireside chat will be publicly accessible via a webcast, available for replay for 30 days on the Compass Investor Relations website [2][3]

Core Insights - Compass Therapeutics, Inc. presented promising preclinical data on CTX-471, a CD137 agonist antibody, at the AACR Annual Meeting, indicating enhanced efficacy in models of immune checkpoint failure through simultaneous blockade of neo-angiogenesis [1][2][3] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology, with a scientific emphasis on the interplay between angiogenesis, the immune system, and tumor growth [10] Product Development - CTX-471 is currently in a Phase 1b clinical trial for patients with solid tumors that have progressed after at least three months on approved PD-1 or PD-L1 inhibitors, showing partial responses in melanoma, small cell lung cancer, and mesothelioma [5] - The combination of CTX-471 with tovecimig has demonstrated significant anti-tumor efficacy in murine models resistant to conventional immune checkpoint inhibitors, suggesting a potential therapeutic regimen for patients who have failed checkpoint inhibitors [7][9] Mechanism of Action - The combination therapy appears to enhance innate and adaptive anti-tumor immunity, including increased tumor cell killing and interferon signaling, which may provide clinical benefits for patients previously unresponsive to standard treatments [3][7] Ongoing Trials - The ongoing COMPANION-002 trial is evaluating the efficacy of tovecimig in combination with paclitaxel for patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers [9]

Core Insights - The field of psychedelic medicine is emerging, attracting investor interest due to its potential for growth and innovation [1] - Compass Pathways experienced a 13% increase in share price following the announcement of a completed step in its clinical trial [1] Company Developments - Compass Pathways has completed dosing in a late-stage clinical trial for its psilocybin treatment, COMP005 [2] - The phase 3 trial involves 258 patients with moderate to severe depression who have not responded to at least two prior treatments, with dosing conducted at 32 sites in the U.S. [3][4] - The company is expected to publish six-week primary endpoint results by the end of June [3] Industry Context - The CEO of Compass Pathways emphasized the milestone as critical in addressing the unmet need in treatment-resistant depression, highlighting the legitimacy of psychedelics as potential therapies for serious psychological disorders [5]